Does Dupilumab Cause Cutaneous T-Cell Lymphoma?

Dr. Cecilia Roka discusses the controversial relationship between dupilumab, an anti-IL-4 receptor antibody used primarily for atopic dermatitis, and cutaneous T-cell lymphoma (CTCL). She outlines that while dupilumab has shown promise in treating conditions related to TH-2 biased diseases like eczema, there are significant concerns regarding its association with CTCL. Current evidence mainly consists of anecdotal reports and small case studies suggesting potential rapid progression of CTCL following dupilumab treatment, with a number of cases misdiagnosed. Roka explains three hypotheses: dupilumab may cause CTCL, unmask pre-existing CTCL, or exacerbate misdiagnosed conditions. Methodological challenges in past studies that examined CTCL risk in patients with atopic dermatitis treated with dupilumab further complicate understanding this relationship. Importantly, she highlights the necessity of having thorough diagnostic workups for patients with suspected CTCL, including flow cytometry, and recommends caution in prescribing dupilumab for eczema in at-risk populations. Ultimately, while some improvements were noted in patients on dupilumab, especially for itch and quality of life, Roka concludes that initial improvement does not rule out CTCL, suggesting a careful reevaluation of symptoms is essential. She advocates for further research, emphasizing that although dupilumab's effect on CTCL remains uncertain, misdiagnosis remains a significant concern that needs addressing.